Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives

Author(s): Da-Yong Lu*, Ting-Ren Lu, Jian Ding, Bin Xu, Jin-Yu Che, Hong-Ying Wu

Journal Name: Current Drug Therapy

Volume 10 , Issue 1 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Background: Clinical cancer treatment and therapy have been gradually improved by experimental and clinical advancements worldwide, especially after the advent of different types of individualized cancer therapy (ICT).

Objective: Despite the longest history of anticancer drug sensitivity testing (DST) among ICT, its therapeutic applications for clinical cancer trials need to be updated.

Methods: DST techniques are widely diversified and improved a great deal, but they have not been matured to cure all cancer patients in clinics.

Results: The retrospection and panorama of historic and evolutionary developments of DST including clinical relevance, advantageous, technical cautions, limitations of varied models and methodologies at present stage are addressed.

Conclusion: Future directions and novel ideas must be established.

Keywords: Anticancer drugs, cancer stem cell, clinical cancer therapy, drug combinations, drug sensitivity test, individualized cancer therapy, neoplasm metastasis.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 25 August, 2015
Page: [44 - 55]
Pages: 12
DOI: 10.2174/157488551001150825100450

Article Metrics

PDF: 47